These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28916621)

  • 1.
    Pyo A; Yun M; Kim HS; Kim TY; Lee JJ; Kim JY; Lee S; Kwon SY; Bom HS; Kim HS; Kim DY; Min JJ
    J Nucl Med; 2018 Feb; 59(2):340-346. PubMed ID: 28916621
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
    Luo H; England CG; Graves SA; Sun H; Liu G; Nickles RJ; Cai W
    J Nucl Med; 2016 Feb; 57(2):285-90. PubMed ID: 26541778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET Imaging of Tissue Factor in Pancreatic Cancer Using 64Cu-Labeled Active Site-Inhibited Factor VII.
    Nielsen CH; Jeppesen TE; Kristensen LK; Jensen MM; El Ali HH; Madsen J; Wiinberg B; Petersen LC; Kjaer A
    J Nucl Med; 2016 Jul; 57(7):1112-9. PubMed ID: 27013699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR; Gallazzi FA; Ferdani R; Anderson CJ; Quinn TP; Deutscher SL
    Cancer Biother Radiopharm; 2010 Dec; 25(6):693-703. PubMed ID: 21204764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer.
    Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE
    Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Evaluation of CD20 Expression Using
    Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
    J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules.
    Qi S; Hoppmann S; Xu Y; Cheng Z
    Mol Imaging Biol; 2019 Oct; 21(5):907-916. PubMed ID: 30617730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.
    Lee JH; Kim H; Yao Z; Lee SJ; Szajek LP; Grasso L; Pastan I; Paik CH
    Nucl Med Biol; 2015 Nov; 42(11):880-6. PubMed ID: 26307499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein.
    Miao Z; Ren G; Liu H; Jiang L; Cheng Z
    Bioconjug Chem; 2010 May; 21(5):947-54. PubMed ID: 20402512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor.
    Luo H; Hong H; Slater MR; Graves SA; Shi S; Yang Y; Nickles RJ; Fan F; Cai W
    J Nucl Med; 2015 May; 56(5):758-63. PubMed ID: 25840981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors.
    Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z
    Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kruziki MA; Case BA; Chan JY; Zudock EJ; Woldring DR; Yee D; Hackel BJ
    Mol Pharm; 2016 Nov; 13(11):3747-3755. PubMed ID: 27696863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines.
    Eiblmaier M; Meyer LA; Watson MA; Fracasso PM; Pike LJ; Anderson CJ
    J Nucl Med; 2008 Sep; 49(9):1472-9. PubMed ID: 18703609
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.